<DOC>
	<DOC>NCT00236067</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of an investigational anti-anxiety medication relative to placebo in patients with generalized anxiety disorder (GAD).</brief_summary>
	<brief_title>A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Tiagabine</mesh_term>
	<criteria>â€¢ Subjects 18 to 64 years of age (inclusive) will be eligible to participate if they satisfy the DSMIVTR criteria for GAD, as well as meeting the required screening and baseline visit scores for a series of psychiatric evaluations (i.e., HAMA, HADS, MADRS and CGIS). Have been previously unresponsive to two or more adequate courses of pharmacological treatment for GAD Have been diagnosed with any other psychiatric Axis I disorder (except GAD) as a principal diagnosis within the past six months Have been diagnosed with any eating disorder within the past six months Have any history of OCD, psychotic disorder, bipolar disorder or antisocial personality disorder Have any history of alcohol or substance abuse within 3 months of screening Have any history of seizures, including febrile seizures Have any history of head trauma associated with loss of consciousness within the past 15 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>